1. Psyence BioMed achieved key milestones and clinical progress in 2025. 2. They advanced a Phase IIb trial for psilocybin-assisted therapy. 3. The company has a unique focus on longevity science investment. 4. Psyence became debt-free with over $9 million cash reserves. 5. Regulatory developments in Australia could enhance therapy access.
FAQ
Why Bullish?
Psyence's advances in clinical trials and manufacturing enhance growth prospects, drawing investor interest.
How important is it?
The article highlights strategic advancements and regulatory environments that could significantly influence PBM's market position.
Why Long Term?
Strong foundations in clinical trials and longevity can lead to sustained growth in upcoming years.
Psyence BioMed Marks Major Milestones and Sets Ambitious Plans for 2026
NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a significant year-end update from its Chief Executive Officer Jody Aufrichtig. The letter highlights the company's impressive achievements in 2025 and outlines its strategic direction for 2026, marking what Aufrichtig refers to as a “turning point” for the organization.
2025 Achievements and Company Overview
Psyence BioMed, a leading biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies, made notable strides in both clinical execution and global manufacturing partnerships. Aufrichtig emphasized the Company’s commitment to addressing unmet mental health needs through psychedelic therapeutics.
Key highlights from 2025 include:
- Initiation of the Phase IIb trial for psilocybin-assisted psychotherapy in Adjustment Disorder.
- Investment in PsyLabs, ensuring a reliable supply chain for psychedelic compounds.
- Investment in sustainable ibogaine sourced in Africa, a unique position among publicly traded companies.
- Debt-free status with cash reserves exceeding USD $9 million.
Clinical Progress and Phase IIb Trial
Psyence BioMed successfully advanced its Phase IIb clinical trial aimed at treating Adjustment Disorder in palliative care. This trial involved multiple patients dosed across various Australian sites, bolstered by a partnership with Southern Star Research, an esteemed clinical research organization in Australia.
Strengthening Manufacturing and Supply Chain
The Company has made significant investments into PsyLabs, enhancing its vertical integration strategy. These investments secure good manufacturing practices (GMP) compliant sources for nature-derived psilocybin and ibogaine, laying a strong foundation for both current and future projects. Additionally, Psyence BioMed achieved a breakthrough in producing high-purity ibogaine, solidifying its manufacturing capabilities.
Regulatory Developments in Australia
In his letter, Aufrichtig highlighted the importance of the Australian Therapeutic Goods Administration’s (TGA) public consultation regarding psilocybin-assisted therapy for patients experiencing existential distress due to life-limiting illnesses. Should this amendment be approved, it would facilitate supervised access through the Authorised Prescriber framework, expanding the eligible prescriber group to include specialists in palliative care.
Psyence’s Leadership in Longevity Science
Psyence BioMed distinguishes itself as a leader in the convergence of psychedelic therapy and longevity science. Aufrichtig remarked, “We are the only publicly listed psychedelics company investing meaningfully in longevity science,” emphasizing the role of psychedelic-assisted therapy in enhancing healthspan—not just lifespan.
Outlook for 2026
Looking ahead, Psyence BioMed aims to:
- Accelerate enrollment in its Phase IIb clinical trial.
- Expand its manufacturing capabilities.
- Pursue new longevity-focused indications.
- Explore strategic partnerships.
Accessing the Full CEO Letter
The complete letter from CEO Jody Aufrichtig is available on the Company’s website at www.psyencebiomed.com.
About Psyence BioMed
Psyence Biomedical Ltd. (Nasdaq: PBM) is a vertically integrated biopharmaceutical company pioneering psychedelic-based therapeutics. As the first life sciences biotechnology firm dedicated to developing nature-derived psilocybin and ibogaine-based medicines listed on Nasdaq, the company is committed to addressing pressing mental health challenges across the spectrum of conditions, especially in palliative care.
Contact Information
For further inquiries, contact Psyence Biomedical Ltd. via email at:
- Investor Relations: ir@psyencebiomed.com
- Media Inquiries: media@psyencebiomed.com
- General Information: info@psyencebiomed.com
- Phone: +1 416-477-1708
Disclaimer
This communication may contain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including projections regarding future performance and operations. Actual results may differ materially due to various factors, including market and regulatory changes.